Moderna (MRNA) said late Friday it has been awarded $590 million by the US Department of Health and Human Services for the development of mRNA-based influenza vaccines.
The project will back the late-stage development and licensure of pre-pandemic mRNA-based vaccines and support the expansion of trials for up to five additional subtypes of pandemic influenza, the company said.
Moderna said that it launched a phase 1/2 trial in 2023 to get safety and immunogenicity data of a candidate pandemic influenza vaccine, mRNA-1018, in adults. The trial included vaccine candidates against the H5 and H7 bird flu viruses.
Based on positive preliminary results from the phase 1/2 trial, the company said it is preparing to move mRNA-1018 into phase 3.
Moderna shares were rising 3.7% in after-hours activity.
Price: 35.31, Change: +1.25, Percent Change: +3.67
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。